- Home
- GNS vs ANTX Comparison
GNS vs ANTX Comparison
Compare GNS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- ANTX
- Stock Information
- Founded
- GNS 2002
- ANTX 2017
- Country
- GNS Singapore
- ANTX United States
- Employees
- GNS N/A
- ANTX N/A
- Industry
- GNS Other Consumer Services
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- GNS Real Estate
- ANTX Health Care
- Exchange
- GNS Nasdaq
- ANTX Nasdaq
- Market Cap
- GNS 36.1M
- ANTX 37.6M
- IPO Year
- GNS 2022
- ANTX 2022
- Fundamental
- Price
- GNS $0.42
- ANTX $1.13
- Analyst Decision
- GNS
- ANTX Hold
- Analyst Count
- GNS 0
- ANTX 5
- Target Price
- GNS N/A
- ANTX $3.50
- AVG Volume (30 Days)
- GNS 5.7M
- ANTX 149.8K
- Earning Date
- GNS 12-27-2024
- ANTX 03-27-2025
- Dividend Yield
- GNS N/A
- ANTX N/A
- EPS Growth
- GNS N/A
- ANTX N/A
- EPS
- GNS N/A
- ANTX N/A
- Revenue
- GNS $16,147,348.00
- ANTX N/A
- Revenue This Year
- GNS $39.87
- ANTX N/A
- Revenue Next Year
- GNS $32.96
- ANTX N/A
- P/E Ratio
- GNS N/A
- ANTX N/A
- Revenue Growth
- GNS N/A
- ANTX N/A
- 52 Week Low
- GNS $0.32
- ANTX $0.87
- 52 Week High
- GNS $6.97
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- GNS 40.37
- ANTX 44.20
- Support Level
- GNS $0.42
- ANTX $1.09
- Resistance Level
- GNS $0.54
- ANTX $1.20
- Average True Range (ATR)
- GNS 0.06
- ANTX 0.05
- MACD
- GNS 0.01
- ANTX 0.01
- Stochastic Oscillator
- GNS 44.44
- ANTX 52.98
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.